PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma

被引：6

作者：

Zhong, Yu-Min ^{[1
,2
,3
]}

Yin, Kai ^{[2
,4
]}

Chen, Yu ^{[2
,3
]}

Xie, Zhi ^{[2
,3
]}

Lv, Zhi-Yi ^{[2
,3
]}

Yang, Jin-Ji ^{[2
]}

Yang, Xue-Ning ^{[2
]}

Zhou, Qing ^{[2
]}

Wang, Bin-Chao ^{[2
]}

Zhong, Wen-Zhao ^{[2
]}

Gao, Ling-Ling ^{[2
,4
]}

Zhou, Wen-Bin ^{[2
]}

Chen, Ji ^{[2
,4
]}

Tu, Hai-Yan ^{[2
]}

Liao, Ri-Qiang ^{[2
]}

Zhang, Dong-Kun ^{[5
]}

Zhang, Shui-Lian ^{[2
,3
]}

Lu, Dan-Xia ^{[2
,3
]}

Zheng, Hong-Bo ^{[6
]}

Zhang, Heng-Hui ^{[6
]}

Wu, Yi-Long ^{[2
]}

Zhang, Xu-Chao ^{[1
,2
,3
,4
]}

机构：

[1] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Cardiovasc Inst, Guangzhou, Peoples R China

[2] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Canc Ctr, Guangzhou, Peoples R China

[3] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Med Res Ctr, Guangzhou, Peoples R China

[4] Southern Med Univ, Sch Clin Med 2, Guangzhou, Peoples R China

[5] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Thorac Surg, Guangzhou, Peoples R China

[6] Genecast Biotechnol, Dept Med Affairs, Wuxi, Peoples R China

来源：

FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷

基金：

中国国家自然科学基金;

关键词：

Lymphoepithelioma-like carcinoma; PD-1; PD-L1; inhibitors; LAG3; CELL LUNG-CANCER; NIVOLUMAB; CHEMOTHERAPY; EXPRESSION; THERAPY; PD-L1; EGFR; IMMUNOTHERAPY; PEMBROLIZUMAB; MUTATION;

D O I：

10.3389/fimmu.2022.951817

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Primary pulmonary lymphoepithelioma-like carcinoma (PLELC) is an Epstein-Barr virus (EBV)-related, rare subtype of non-small-cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICI) show durable responses in advanced NSCLC. However, their effects and predictive biomarkers in PLELC remain poorly understood. We retrospectively analyzed the data of 48 metastatic PLELC patients treated with ICI. Pretreated paraffin-embedded specimens (n = 19) were stained for PD-1, PD-L1, LAG3, TIM3, CD3, CD4, CD8, CD68, FOXP3, and cytokeratin (CK) by multiple immunohistochemistry (mIHC). Next-generation sequencing was performed for 33 PLELC samples. Among patients treated with ICI monotherapy (n = 30), the objective response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), and overall survival (mOS) were 13.3%, 80.0%, 7.7 months, and 24.9 months, respectively. Patients with PD-L1 >= 1% showed a longer PFS (8.4 vs. 2.1 months, p = 0.015) relative to those with PD-L1 <1%. Among patients treated with ICI combination therapy (n = 18), ORR, DCR, mPFS, and mOS were 27.8%, 100.0%, 10.1 months, and 19.7 months, respectively. Patients with PD-L1 >= 1% showed a significantly superior OS than those with PD-L1 <1% (NA versus 11.7 months, p = 0.001). Among the 19 mIHC patients, those with high PD-1/PD-L1 and LAG3 expression showed a longer PFS (19.0 vs. 3.9 months, p = 0.003). ICI also showed promising efficacy for treating metastatic PLELC. PD-L1 may be both predictive of ICI treatment efficacy and prognostic for survival in PLELC. PD-1/PD-L1 combined with LAG3 may serve as a predictor of ICI treatment effectiveness in PLELC. Larger and prospective trials are warranted to validate both ICI activity and predictive biomarkers in PLELC.This study was partly presented as a poster at the IASLC 20th World Conference on Lung Cancer 2019, 7-10 September 2019, Barcelona, Spain.

引用

页数：12

共 50 条

[21] Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Dongxu Wang
Jianzhen Lin
Xu Yang
Junyu Long
Yi Bai
Xiaobo Yang
Yilei Mao
Xinting Sang
Samuel Seery
Haitao Zhao
Journal of Hematology & Oncology, 12
[22] Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond
Aden, Durre
Zaheer, Samreen
Sureka, Niti
Trisal, Monal
Chaurasia, Jai Kumar
Zaheer, Sufian
PATHOLOGY RESEARCH AND PRACTICE, 2025, 269
[23] Covalent small-molecule inhibitors of the PD-1/PD-L1 immune checkpoint
Maslanka, A.
Kitel, R.
Konopka, J.
Skalniak, L.
FEBS OPEN BIO, 2024, 14 : 329 - 330
[24] PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review
Caccese, Mario
Indraccolo, Stefano
Zagonel, Vittorina
Lombardi, Giuseppe
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 135 : 128 - 134
[25] PD-L1 and LAG3 Expression in Hepatocellular Carcinoma Associated with HCV and Steatohepatitis
Xing, Dongmei
Luan, Lan
Zhu, Qingfeng
Gani, Faiz
Pawlik, Timothy
Taube, Janis M.
Anders, Robert A.
LABORATORY INVESTIGATION, 2017, 97 : 426A - 426A
[26] Immune checkpoint inhibitors targeting PD-1/PD-L1 in the treatment of human lymphomas
Ribatti, Domenico
Cazzato, Gerardo
Tamma, Roberto
Annese, Tiziana
Ingravallo, Giuseppe
Specchia, Giorgina
FRONTIERS IN ONCOLOGY, 2024, 14
[27] The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Mahoney, Kathleen M.
Freeman, Gordon J.
McDermott, David F.
CLINICAL THERAPEUTICS, 2015, 37 (04) : 764 - 782
[28] Anti PD-1/PD-L1 Immune checkpoint inhibitors - addition - EML and EMLc
SELECTION AND USE OF ESSENTIAL MEDICINES: REPORT OF THE WHO EXPERT COMMITTEE ON SELECTION AND USE OF ESSENTIAL MEDICINES, 2019 (INCLUDING THE 21ST WHO MODEL LIST OF ESSENTIAL MEDICINES AND THE 7TH WHO MODEL LIST OF ESSENTIAL MEDICINES FOR CHILDREN), 2019, 1021 : 314 - 331
[29] Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer
AmeliMojarad, Mandana
AmeliMojarad, Melika
Cui, Xiaonan
PATHOLOGY RESEARCH AND PRACTICE, 2023, 244
[30] PD-L1 and LAG3 Expression in Hepatocellular Carcinoma Associated with HCV and Steatohepatitis
Xing, Dongmei
Luan, Lan
Zhu, Qingfeng
Gani, Faiz
Pawlik, Timothy
Taube, Janis M.
Anders, Robert A.
MODERN PATHOLOGY, 2017, 30 : 426A - 426A

← 1 2 3 4 5 →